Broader patient population target opportunity for Shield Therapeutics’s Feraccru in Europe

Shield Therapeutics’s Feraccru can now be used as a treatment of all adults with iron deficiency (ID) as the company said the European Commission  (EC) has adopted the Decision to extend the approved indication for Feraccru.

Adoptin this extension of Feraccru’s marketing authorisation approval, will provide Feraccru with a much broader commercial opportunity, as previously it was only approved and marketed in Europe for the treatment of iron deficiency anemia (IDA) in adult patients with inflammatory bowel disease (IBD), the company said in its press release.

Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: “We are extremely pleased that following the CHMP positive opinion in February, the EU Commission has so rapidly ratified the expansion of the indication for Feraccru.  This decision confirms a significantly broader patient population target opportunity for Feraccru in Europe, where 40 million people are estimated to be iron deficient.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.